Entero Healthcare Solutions Ltd. Q1 FY27 Results

Revenue: INR 1,940 crore (Up 38.2% YoY)
PAT: INR 52 crore (Up 72% YoY)

Reader Takeaway: Strong revenue growth and early margin target achievement, balanced by integration and seasonality concerns.

What just happened

Entero Healthcare Solutions started FY27 with significant growth, reporting a consolidated revenue of INR 1,940 crore, a 38.2% increase year-on-year. On a like-for-like basis, the growth was 40%. The company also saw its Profit after Tax (PAT) surge by 72% year-on-year to INR 52 crore, with a PAT margin of 2.7%.

Why this matters

The company's performance highlights a strategic shift towards operational efficiency and organic growth. Achieving the full-year EBITDA margin guidance of 5% in the first quarter, a 143 basis point improvement, signals strong operational execution. Significant improvements in ROCE and ROE, alongside reduced working capital days, underscore this efficiency.

The backstory

Entero Healthcare Solutions has been actively involved in mergers and acquisitions (M&A) in recent years. For FY27, the strategy pivots to consolidating and integrating these past acquisitions, with a focus on organic expansion in the near term. The MedTech segment is a key growth area, aiming to contribute over INR 1,000 crore in revenue for FY27.

What changes now

The company's focus shifts to leveraging its existing distribution network and integrating its acquired entities. While new acquisitions are not ruled out, particularly in the last quarter, the immediate priority is organic growth, which was 17.8% reported (19.6% like-for-like) in Q1, outperforming the pharmaceutical market growth of 13.8%.

Risks to watch

• Seasonality: Q2 typically sees higher business volumes than Q1 in the pharma industry, which could impact sequential growth comparisons.
• Integration: The company continues to manage call options for acquiring minority stakes in subsidiaries over the next 2-5 years, which requires ongoing management attention.
• Industry Growth Uncertainty: While industry growth has turned to double-digits, the sustainability of this trend remains unclear to management.

Peer comparison

• Entero Healthcare's reported organic revenue growth of 17.8% (like-for-like 19.6%) outperformed the underlying pharmaceutical market growth of 13.8% in Q1 FY27.

Context metrics (time-bound)

• Revenue Growth (YoY): 38.2% (40% on like-for-like basis)
• EBITDA Margin: 5% (143 bps YoY improvement)
• PAT Growth (YoY): 72%
• Net Working Capital Days: 61 (down from 66 YoY)
• ROCE: 21.1% (vs 11.5% YoY)
• ROE: 20.4% (vs 9% YoY)
• MedTech Revenue Target: INR 1,000 crore in FY27

What to track next

Investors will be watching Entero Healthcare's ability to sustain its improved EBITDA margins and manage the integration of its acquired businesses. Monitoring organic growth against industry benchmarks and the performance of the MedTech segment will also be crucial.